Darrell R. Abernethy

Darrell R. Abernethy's AcademicInfluence.com Rankings

Medical

#1738

World Rank

#2109

Historical Rank

Pharmacology

#159

World Rank

#198

Historical Rank

medical Degrees

Download Badge

Medical

Darrell R. Abernethy's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Darrell R. Abernethy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Darrell R. Abernethy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels (2003) (7161)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans (2010) (626)
A drug burden index to define the functional burden of medications in older people. (2007) (559)
Effect of Age, Gender, and Obesity on Midazolam Kinetics (1984) (558)
Current Status of Benzodiazepines (1983) (403)
Active Nitric Oxide Produced in the Red Cell under Hypoxic Conditions by Deoxyhemoglobin-mediated Nitrite Reduction* (2003) (344)
Pharmacokinetics and Clinical Effectiveness of Methylphenidate (1999) (306)
Calcium-antagonist drugs. (1999) (276)
High‐Risk Prescribing and Incidence of Frailty Among Older Community‐Dwelling Men (2012) (259)
Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats (2006) (230)
Drug burden index score and functional decline in older people. (2009) (207)
Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic (2011) (199)
Drug therapy. Current status of benzodiazepines. (1983) (193)
The utility of modeling and simulation in drug development and regulatory review. (2013) (191)
Total Protein Methods and Their Potential Utility to Reduce the Risk of Food Protein Adulteration. (2010) (172)
Drug Disposition in Obese Humans (1986) (171)
Physical and Cognitive Performance and Burden of Anticholinergics, Sedatives, and ACE Inhibitors in Older Women (2008) (158)
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. (1983) (150)
The pharmacokinetic profile of amlodipine. (1989) (147)
Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives (2004) (147)
The Pharmacokinetics of Midazolam in Chronic Renal Failure Patients (1983) (142)
Drug Burden Index and physical function in older Australian men. (2009) (135)
Pharmacokinetics of Drugs in Obesity (1982) (133)
Imipramine and desipramine disposition in the elderly. (1985) (133)
Alterations in drug distribution and clearance due to obesity. (1981) (131)
Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. (1982) (128)
Diazepam kinetics in relation to age and sex. (1981) (123)
Obesity, sex, and acetaminophen disposition (1982) (123)
Clinical Pharmacokinetics of the Newer Benzodiazepines (1983) (121)
Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. (1986) (119)
Systems pharmacology to predict drug toxicity: integration across levels of biological organization. (2013) (117)
Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. (2002) (114)
Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. (1983) (112)
Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium. (1987) (111)
Alprazolam kinetics in the elderly. Relation to antipyrine disposition. (1983) (109)
Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. (1982) (107)
Metal Impurities in Food and Drugs (2010) (105)
Molecular Determinants of L-type Ca2+ Channel Inactivation (1998) (103)
Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. (1983) (103)
Effects of amlodipine, a long‐acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition (1990) (101)
Effects of the physical work environment on physiological measures of stress (2010) (98)
Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. (1983) (97)
Structure-functional diversity of human L-type Ca2+ channel: perspectives for new pharmacological targets. (2002) (96)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation (2012) (93)
Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. (1983) (91)
Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat (1984) (90)
High-performance liquid chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. (1981) (89)
Digoxin disposition in obesity: clinical pharmacokinetic investigation. (1981) (89)
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. (1983) (89)
The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam (1984) (89)
Acetaminophen kinetics in the elderly (1982) (88)
Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development (2007) (87)
Stereochemistry of an Agonist Determines Coupling Preference of β2-Adrenoceptor to Different G Proteins in Cardiomyocytes (2009) (87)
Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. (1985) (86)
Atherosclerosis-related molecular alteration of the human CaV1.2 calcium channel α1C subunit (2006) (84)
Hypothyroidism Is a Risk Factor for New-Onset Diabetes: A Cohort Study (2015) (82)
Impairment of lidocaine clearance in elderly male subjects. (1983) (80)
Plasma protein binding of drugs after severe burn injury (1984) (79)
Geriatric drug evaluation: where are we now and where should we be in the future? (2011) (78)
Lidocaine disposition in obesity. (1984) (77)
Prolonged Accumulation of Diazepam in Obesity (1983) (76)
Phenytoin disposition in obesity. Determination of loading dose. (1985) (76)
Pharmacokinetics and pharmacodynamics of amlodipine. (1992) (76)
Serum protein signatures detect early radiographic osteoarthritis. (2009) (74)
Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (1997) (71)
Pharmacokinetics of Calcium Antagonists Under Development (1988) (69)
Responses to intravenous and oral diltiazem in elderly and younger patients with systemic hypertension. (1987) (69)
Voltage-gated Mobility of the Ca2+ Channel Cytoplasmic Tails and Its Regulatory Role* (2003) (69)
Bidirectional interactions between indomethacin and the murine intestinal microbiota (2015) (68)
A Pilot Randomized Clinical Trial Utilizing the Drug Burden Index to Reduce Exposure to Anticholinergic and Sedative Medications in Older People (2010) (67)
Imipramine disposition in users of oral contraceptive steroids (1984) (67)
Absolute and relative bioavailability of oral acetaminophen preparations. (1983) (67)
β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease (2018) (65)
Aging is associated with endothelial dysfunction in the human forearm vasculature. (2000) (65)
Drug Burden Index and Beers Criteria: Impact on Functional Outcomes in Older People Living in Self‐Care Retirement Villages (2012) (65)
Differential Role of the α1C Subunit Tails in Regulation of the Cav1.2 Channel by Membrane Potential, β Subunits, and Ca2+ Ions* (2005) (64)
Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults. (2012) (64)
Absorption and disposition of ibuprofen in the elderly. (1984) (64)
An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation. (1996) (62)
Effect of Food on Acetaminophen Absorption in Young and Elderly Subjects (1982) (61)
Pharmacological Mechanism‐Based Drug Safety Assessment and Prediction (2011) (60)
Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. (2007) (59)
Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. (2000) (59)
Electromyographic patterns suggest changes in motor unit physiology associated with early osteoarthritis of the knee. (2007) (58)
Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine (1986) (57)
Age Does Not Alter Acetaminophen Absorption (1982) (55)
Cardiovascular Effects of and Interaction Between Calcium Blocking Drugs and Anesthetics in Chronically Instrumented Dogs. IV. Chronically Administered Oral Verapamil and Halothane, Enflurane, and Isoflurane (1987) (55)
Ibuprofen disposition in obese individuals. (1985) (54)
Impairment of antipyrine metabolism by low‐dose oral contraceptive steroids (1981) (54)
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation (2001) (54)
Glutathione is a cofactor for H2O2-mediated stimulation of Ca2+-induced Ca2+ release in cardiac myocytes. (1998) (54)
Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. (1993) (53)
Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). (1982) (53)
Age Effects on Alpha‐1‐Acid Glycoprotein Concentration and Imipramine Plasma Protein Binding (1984) (53)
Lorazepam and oxazepam kinetics in women on low‐dose oral contraceptives (1983) (52)
Pharmacokinetic aspects of drug therapy in the elderly. (1986) (52)
Impaired endothelial‐dependent forearm vascular relaxation in black Americans (1999) (52)
Midazolam pharmacology and pharmacokinetics (1985) (51)
Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5 (2016) (51)
Caffeine disposition in obesity. (1985) (49)
Functional coupling of human L-type Ca2+ channels and angiotensin AT1A receptors coexpressed in xenopus laevis oocytes: involvement of the carboxyl-terminal Ca2+ sensors. (1998) (47)
Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty (2003) (47)
In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods. (2017) (46)
Increased Metabolic Clearance of Acetaminophen with Oral Contraceptive Use (1982) (46)
Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. (1981) (46)
Interaction of propoxyphene with diazepam, alprazolam and lorazepam. (1985) (45)
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. (1988) (44)
Benzodiazepine hypnotics: kinetic and therapeutic options. (1982) (43)
Pediatric Dose Selection (2010) (42)
Caloric restriction reduces age-related pseudocapillarization of the hepatic sinusoid (2007) (42)
The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma (1986) (42)
P-Glycoprotein in clinical cardiology. (1999) (41)
Verapamil pharmacodynamics and disposition in obese hypertensive patients. (1988) (41)
Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. (1986) (41)
Calcium antagonists in geriatric patients: Diltiazem in elderly persons with hypertension (1989) (40)
Effect of angiotensin-converting enzyme insertion/deletion polymorphism DD genotype on high-frequency heart rate variability in African Americans. (2003) (40)
Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop (2018) (40)
Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. (1997) (39)
Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. (1987) (39)
Cimetidine Impairs Clearance of Antipyrine and Desmethyldiazepam in the Elderly (1982) (39)
N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. (1987) (39)
Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. (1984) (39)
Serum haloperidol concentrations and clinical response in acute psychosis. (1984) (38)
Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: Relation to lipid solubility (1985) (38)
Selective inhibition of warfarin metabolism by diltiazem in humans. (1991) (37)
Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (1985) (37)
An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. (1994) (36)
Voltage-gated rearrangements associated with differential beta-subunit modulation of the L-type Ca(2+) channel inactivation. (2004) (36)
New short splice variants of the human cardiac Cavbeta2 subunit: redefining the major functional motifs implemented in modulation of the Cav1.2 channel. (2004) (36)
Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. (2001) (35)
Physiologic Changes in Old Age: Relation to Altered Drug Disposition (1982) (35)
HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. (2007) (35)
Pharmacokinetics of alprazolam. (1983) (35)
Increased cimetidine clearance in burn patients. (1985) (34)
Trimipramine kinetics and absolute bioavailability: Use of gas‐liquid chromatography with nitrogen‐phosphorus detection (1984) (34)
Triazolam and ethanol interaction: Kinetic and dynamic consequences (1985) (33)
Plasma adenosine deaminase2: a marker for human immunodeficiency virus infection. (1991) (33)
An investigation of the cause of accumulation of verapamil during regular dosing in patients. (1985) (33)
Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. (1989) (33)
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. (1984) (31)
Functional food ingredient quality: Opportunities to improve public health by compendial standardization (2009) (31)
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. (1997) (31)
Structure-activity relationship of ligands of human plasma adenosine deaminase2. (1991) (30)
Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium (1997) (29)
Assessment and reporting of clinical pharmacology information in drug labeling (2000) (28)
Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (1998) (27)
Diltiazem and captopril alone or in combination for treatment of mild to moderate systemic hypertension. (1988) (27)
Cimetidine impairs nitrazepam clearance (1983) (27)
Diltiazem and desacetyldiltiazem analysis in human plasma using high-performance liquid chromatography: improved sensitivity without derivation. (1985) (27)
Pharmacokinetic properties of benzodiazepine hypnotics. (1983) (27)
Acute and chronic studies of diltiazem in elderly versus young hypertensive patients. (1987) (26)
Pharmacokinetics of benzodiazepine hypnotics. (1982) (26)
Treatment of diazepam withdrawal syndrome with propranolol. (1981) (25)
Exendin-4 Pharmacodynamics: Insights from the Hyperglycemic Clamp Technique (2004) (25)
Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue. A comparison with plasma concentrations in the rat. (1983) (25)
Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. (2006) (24)
Tyrosine kinase-targeting drugs-associated heart failure (2017) (24)
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells (2015) (23)
Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects (2002) (23)
Cimetidine disposition in obesity. (1984) (23)
Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipyrine, diazepam, and lorazepam (1984) (23)
Making sense of trueness, precision, accuracy, and uncertainty (2008) (23)
Noninteraction of temazepam and cimetidine. (1984) (23)
Diphenhydramine determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single low-dose pharmacokinetic studies. (1983) (23)
Endothelin-1 induces an increase in total protein synthesis and expression of the smooth muscle alpha-actin gene in vascular smooth muscle cells. (1996) (23)
Differential role of the alpha1C subunit tails in regulation of the Cav1.2 channel by membrane potential, beta subunits, and Ca2+ ions. (2005) (23)
Calcium antagonists block angiotensin II-mediated vasoconstriction in humans: comparison with their effect on phenylephrine-induced vasoconstriction. (1992) (23)
Is Volume of Distribution at Steady State a Meaningful Kinetic Variable? (1983) (23)
Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. (2000) (22)
Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs: VII. Verapamil and thiopental. (1986) (22)
Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: application to single-dose pharmacokinetic studies. (1981) (22)
Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. (1984) (22)
Effects of Inhalational Anesthetics on Verapamil Pharmacokinetics in Dogs (1986) (22)
Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. (1991) (22)
Interaction of Cimetidine with Oxazepam, Lorazepam, and Flurazepam (1984) (22)
Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics (2007) (22)
Aging and Medications: Past, Present, Future (2009) (21)
Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors (2016) (21)
Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells. (1998) (21)
High-performance liquid chromatographic determination of diltiazem and its major metabolites, N-monodemethyldiltiazem and desacetyldiltiazem, in plasma. (1987) (21)
Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. (1990) (21)
Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies. (1984) (20)
Drug Burden Index and Its Association With Hip Fracture Among Older Adults: A National Population-Based Study. (2018) (19)
Grapefruits and drugs: when is statistically significant clinically significant? (1997) (19)
Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats. (1987) (19)
Needs for an Expanded Ontology‐Based Classification of Adverse Drug Reactions and Related Mechanisms (2012) (19)
Drug Burden and its Association with Falls Among Older Adults in New Zealand: A National Population Cross-Sectional Study (2017) (19)
Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. (1988) (19)
Benzodiazepine drug-drug interactions commonly occurring in clinical practice. (1984) (19)
Pharmacokinetic Investigations in Elderly Patients Clinical and Ethical Considerations (1990) (19)
Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam (1983) (18)
Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites (1988) (18)
Liver injury due to verapamil. (1988) (18)
Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. (1990) (18)
Notes of the American Society for Clinical Pharmacology and Therapeutics (1991) (17)
Plasma adenosine deaminase2, is a marker for human immunodeficiency virus‐1 seroconversion (1991) (17)
Endothelin‐I—mediated vasoconstriction: Specific blockade by verapamil (1992) (17)
Minoxidil analysis in human plasma using high-performance liquid chromatography with electrochemical detection. Application to pharmacokinetic studies. (1986) (17)
Verapamil blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle cells. (1992) (17)
Labetalol in the Treatment of Hypertension in Elderly and Younger Patients (1987) (16)
Kinetics of low-dose intravenous antipyrine: use of liquid chromatography. (1983) (16)
Impairment of hepatic drug oxidation by propoxyphene. (1982) (16)
Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. (1986) (15)
Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships. (1989) (15)
Ticlopidine inhibits phenytoin clearance (1999) (15)
Moexipril in the Treatment of Mild to Moderate Essential Hypertension: Comparison with Sustained‐Release Verapamil (1995) (15)
Revision of instructions to authors for pharmacology research and perspectives: enhancing the quality and transparency of published work (2015) (15)
Lidocaine determination in human plasma with application to single low-dose pharmacokinetic studies. (1982) (14)
Obesity effects on nitrazepam disposition. (1986) (14)
Plasma levels of trazodone: methodology and applications. (1984) (14)
Pharmacological properties of combination therapies for hypertension. (1997) (14)
New Molecular Determinant for Inactivation of the Human L-Type α1C Ca2+ Channel (2000) (14)
Pharmacogenomics and adverse drug reactions. (2010) (14)
Effects of desmethyldiazepam on diazepam kinetics: A study of effects of a metabolite on parent drug disposition (1981) (14)
Lack of interaction between verapamil and cimetidine (1985) (14)
Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology (2015) (14)
Haloperidol determination in serum and cerebrospinal fluid using gas--liquid chromatography with nitrogen--phosphorus detection: application to pharmacokinetic studies. (1984) (14)
Kullback-Leibler clustering of continuous wavelet transform measures of heart rate variability. (2004) (14)
Aging effects on drug disposition and effect. (1999) (14)
Local angiotensin‐converting enzyme inhibition blunts endothelin‐1–induced increase in forearm vascular resistance (1995) (14)
Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome (2015) (14)
Use of Biomedical Ontologies for Integration of Biological Knowledge for Learning and Prediction of Adverse Drug Reactions (2017) (13)
Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. (1983) (13)
Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. (1986) (13)
Role of isoflurane on hemodynamic properties and disposition of nicardipine. (1987) (13)
Influence of Oral Contraceptive Use and Cigarette Smoking, Alone and Together, on Antipyrine Pharmacokinetics (1997) (13)
Angiotensin II Regulates Human Vascular Smooth Muscle α-Actin Gene Expression (1993) (12)
Improving the tools of clinical pharmacology: Goals for 2017 and beyond (2017) (12)
Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Application to single-dose pharmacokinetic studies. (1983) (12)
Cardiovascular Effects of and Interaction Between Calcium Blocking Drugs and Anesthetics in Chronically Instrumented Dogs. VI. Verapamil and Fentanyl‐pancuronium (1988) (12)
Simultaneous determination of lidocaine and its deethylated metabolites using gas-liquid chromatography with nitrogen-phosphorus detection. (1984) (12)
Steady state verapamil tissue distribution in the dog: differing tissue accumulation. (1986) (11)
Acceptable, Equivalent, or Better: Approaches for Alternatives to Official Compendial Procedures (2009) (11)
Lorazepam analysis using liquid chromatography: improved sensitivity for single-dose pharmacokinetic studies. (1986) (11)
Differential Role of the 1 C Subunit Tails in Regulation of the Cav 1 . 2 Channel by Membrane Potential , Subunits , and Ca 2 Ions * □ S (2005) (11)
Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. (1985) (11)
Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. (1987) (11)
Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. (1983) (11)
Dose‐Independent Pharmacokinetics of Intravenous Lidocaine in Humans (1983) (11)
Verapamil decreases lymphocyte protein kinase C activity in humans (1994) (10)
Ketoconazole does not impair antipyrine clearance in humans. (1986) (10)
Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy. (2005) (10)
Adverse Event Detection and Labeling in Pediatric Drug Development (2015) (10)
Application of Systems Pharmacology to Explore Mechanisms of Hepatotoxicity (2014) (10)
Analysis of functional signaling domains from fluorescence imaging and the two-dimensional continuous wavelet transform. (2007) (10)
Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy (1983) (9)
Antipyrine determination in human plasma by gas--liquid chromatography using nitrogen--phosphorus detection. (1981) (9)
Impairment of diazepam clearance with low-dose oral contraceptive steroid therapy (1982) (9)
Labetalol Analysis in Human Plasma Using Liquid Chromatography with Electrochemical Detection: Application to Pharmacokinetic Studies (1986) (9)
Paracetamol absorption from a feeding jejunostomy. (1986) (9)
Effect of drugs which alter microsomal drug-metabolizing enzyme activity on rat hepatic cholesterol biosynthesis. (1977) (9)
Replication – why we need to publish our findings (2015) (9)
Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability (2004) (8)
Close correlation of acetaminophen clearance with that of conjugated benzodiazepines but not oxidized benzodiazepines (2004) (8)
Use of saliva lithium determinations for monitoring lithium therapy. (1978) (8)
Benzodiazepine hypnotic metabolism: drug interactions and clinical implications (1986) (8)
Integration of Diverse Data Sources for Prediction of Adverse Drug Events (2011) (8)
The synthesis of 2,4-diketo-5-phenyl- 5 -7-oxa-1,3-diazabicyclo(4.4.0)decane and 2,4-diketo-3-phenyl- 5 -7-oxa-1,5-diazabicyclo(4.4.0)decane. (1972) (8)
A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012) (2012) (8)
Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network. (2005) (8)
Use of Internet Search Logs to Evaluate Potential Drug Adverse Events (2014) (7)
Metrologic approaches to setting acceptance criteria: unacceptable and unusual characteristics. (2008) (7)
Research Challenges, New Drug Development, Preclinical and Clinical Trials in the Ageing Population (1990) (7)
Absolute bioavailability of imipramine: Influence of food (2004) (7)
Drug Burden Index for International Assessment of the Functional Burden of Medications in Older People (2014) (7)
Antipyretic analgesic drugs as models for studies of drug disposition in old age. (1983) (7)
Forearm vascular α1‐adrenergic blockade by verapamil (1990) (7)
NMR investigation of histamine-phospholipid interaction. (1974) (7)
Advice on statistical analysis, and new journal guidance for experimental design and analysis (2014) (6)
Cardiovascular Effects of and Interaction Between Calcium Blocking Drugs and Anesthetics in Chronically Instrumented Dogs. V. Role of Pharmacokinetics and the Autonomic Nervous System in the Interactions Between Verapamil and Inhalational Anesthetics (1987) (6)
Antipyrine Kinetics in Patients with Primary Biliary Cirrhosis (1993) (6)
Effect of calcium antagonists on RNA synthesis of NIH 3T3 cells. (1993) (6)
Erratum: Stereoselective halofantrine disposition and effect: Concentration-related QTc prolongation (British Journal of Dermatology (2001) 51 (231-237)) (2002) (6)
Performance-based monographs (2009) (6)
Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs. (1985) (6)
New molecular determinant for inactivation of the human L-type alpha1C Ca2+ channel. (2000) (5)
Carvedilol in patients with chronic heart failure. (1996) (5)
Effects of nifedipine on hepatic drug oxidation. (1988) (5)
High-performance liquid chromatographic determination of 3',5'-cyclic adenosine monophosphate in human platelets. (1990) (5)
Drug Therapy in the Elderly (2007) (5)
Effect of penbutolol on lidocaine kinetics. (1983) (5)
Methodological Issues in the Design of Paediatric Pharmacokinetic Studies (2012) (5)
USP Responses to Comments on Stimuli Article, "Proposed Change to Acceptance Criteria for Dissolution Performance Verification Testing" (2008) (5)
Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. (2008) (5)
Differential effects of cimetidine on drug oxidation vs conjugation: Potential mode of therapy for acetaminophen hepatotoxicity (1982) (5)
Verapamil dynamics and disposition in obese hypertensives (1985) (5)
Improving Therapeutics to Better Care for Older Adults and the Young: Report From the American College of Clinical Pharmacology Workshop (2018) (4)
Technology assessment for an integrated PC-based platform for three telemedicine applications (1996) (4)
Polymorphic variant endothelial nitric oxide synthase impairs endothelium dependent vascular relaxation in both heterozygotes and homozygotes (2001) (4)
GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near‐Term Efforts in the Field (2016) (4)
Issue Information (2020) (4)
In vitro inhibition of rat liver cholest-5en-3β-ol (cholesterol) biosynthesis by non-mercurial sulfhydryl reagents (1976) (4)
Notice of Concern (2006) (4)
The effect of propylene glycol on antipyrine clearance in humans (1987) (4)
Narrative Review: The U.S. Pharmacopeia and Model Guidelines for Medicare Part D Formularies (2006) (4)
Forearm vascular alpha 1-adrenergic blockade by verapamil. (1990) (3)
IUPHAR International geriatric clinical pharmacology curriculum for medical students. (2019) (3)
Metabolite-parent drug interaction study: Desmethyldiazepam effect on diazepam kinetics (1981) (3)
Change in Criteria for USP Dissolution Performance Verification Tests (2009) (3)
Thalidomide pharmacokinetics do not change with chronic administration (1997) (3)
Hypothyroidism Is a Risk Factor for New-Onset Diabetes Mellitus: A Cohort Study (2015) (3)
Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects. (2002) (3)
Adenosine deaminase isoenzymes of the opossum Didelphis virginiana: initial chromatographic and kinetic studies. (1995) (3)
Measures of drug toxicity in older adults. (2008) (3)
INHALATIONAL ANESTHETICS (IAs) AFTER THE PHARMACOKINETICS OF VERAPAMIL (V) (1985) (3)
Ibuprofen Does Not Impair Antipyrine Clearance (1983) (3)
Diazepam kinetics in chronic renal failure (1981) (2)
New strategies in cardiovascular disease management: Summary of round table discussion (1997) (2)
Angiotensin II regulates human vascular smooth muscle alpha-actin gene expression. (1993) (2)
Critical drug interactions: A guide to important examples (1993) (2)
Acetaminophen kinetics in obesity (1981) (2)
A practitioner's point of view (1991) (2)
Heparin monographs further revised (2009) (2)
Panel I: The ideal training program (1987) (2)
General chapter management in the 2010-2015 cycle (2009) (2)
Description of the Upcoming Change in Data Analysis for USP Dissolution Performance Verification Tests (2009) (2)
PredicTox: A Systems Pharmacology Project to Examine Cardiotoxicity Associated with Tyrosine Kinase Inhibitors (2017) (1)
Darrell R. Abernethy (1949‐2017) (2018) (1)
Role of Systems Modeling in Regulatory Drug Approval (2016) (1)
Anxiolytic drug therapy in patients with medical disease: clinical importance of pharmacokinetic drug interactions. (1984) (1)
PHARMACOLOGY ACROSS THE AGING CONTINUUM (2009) (1)
The US Pharmacopeia near Infrared System Suitability Reference Standard (2008) (1)
Reducing drugs in older adults is more. (2011) (1)
OPTIMIZED PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES IN CARDIOVASCULAR DISEASE THERAPY (1997) (1)
Drug glucuronidation in obesity (1982) (1)
Speaking of Pharmacology (2006) (1)
A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012) (2012) (1)
Antipyrine kinetics in the elderly: Prediction of benzodiazepine oxidizing capacity (1981) (1)
In Memoriam: David A. Flockhart, 1952–2015 (2016) (1)
Panel I. Drug utilization review: Criteria * (1991) (1)
Lorazepam and oxazepam kinetics in women on lowdose oral contraceptives (1983) (1)
New Short Splice Variants of the Human Cardiac Cavβ2 Subunit (2004) (1)
EFFECT OF LIDOCAINE ON VERAPAMIL PHARMACOKINETICS IN DOGS (1986) (1)
Subject Index, Vol. 36, 1988 (1988) (1)
Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography. (1998) (1)
Nonlinear binding models suggest that ABCIXIMAB (AB) Pharmacokinetics (PK) and pharmacodynamics (PD) are target‐mediated (2004) (1)
Cimetidine impairs drug oxidizing capacity in the elderly (1982) (1)
EFFECT OF VERAPAMIL ON LIDOCAINE PHARMACOKINETICS AND DYNAMICS IN CONSCIOUS DOGS (1987) (1)
Regulating manufacturer‐affiliated communication in the information age (1999) (1)
Effects of gender on propranolol pharmacok1netics and pharmacodynamics (1996) (1)
PI‐11 (2006) (1)
1997 ASCPT Clinical Pharmacology Curriculum Review Course (1996) (0)
Issue Information (2017) (0)
Loratadine/nefazodone interaction. Author's reply (2002) (0)
Nitric oxide (NO) directly inhibits OCT1 DNA binding activity in cultured vascular smooth muscle cells (VSMCs) (1996) (0)
Issue Information (2015) (0)
USP responses to comments on Stimuli article, "Uncertainty Statements Regarding USP Reference Standards" (2008) (0)
Improving food safety through public standards for food ingredients (2008) (0)
Issue Information (2016) (0)
Issue Information (2014) (0)
Contents, Vol. 36, 1988 (1984) (0)
Verapamil (VER) first pass clearance: S‐NOR verapmil (S‐NOR) formation contributes less with age while R‐NOR verapmil (R‐NOR) formation does not change in aging (1996) (0)
Increase in acetaminophen metabolism by low-dose oral contraceptive steroid use (1981) (0)
Issue Information (2014) (0)
Phase I Evaluation of Desbutyihalofantrine in Healthy Volunteers. (1997) (0)
Halofantrine stereoselective clearance and QT prolongation (1999) (0)
Antihypertensive therapy: a look ahead. (1993) (0)
Propoxyphene inhibition of doxepin and antipyrine metabolism (1982) (0)
Medication therapy in older adults (2022) (0)
Metrology and USP dissolution (2008) (0)
Issue Information (2015) (0)
D80 Tasosartan and atenolol: Interaction in hypertensives (1997) (0)
Author Index/Subject Index (2019) (0)
Variability in Human Cardiovascular Pharmacodynamics (1991) (0)
Clinical pharmacologists and health care reform (1993) (0)
Oral Session I‐D (OI‐D) (2007) (0)
Issue Information (2014) (0)
Acknowledgement to Referees (2016) (0)
REPRESENTATIVENESS OF CLINICAL TRIAL POPULATIONS: ARE THESE THE PATIENTS THAT GET TREATED? (2017) (0)
Issue Information (2017) (0)
Issue Information (2013) (0)
Pharmacokinetics of benzodiazepine hypnotics. (1983) (0)
1998 ASCPT Clinical Pharmacology Curriculum Review Course (1997) (0)
Conversion of dimethoxymethyl-diphenylbarbituric acid (DMMDPB) to diphenylbarbituric acid (DPB) in the rat (1996) (0)
Pharmacokinetics and pharamcodynamics of amlodipine (1992) (0)
Issue Information (2014) (0)
“Fundamentals of neurology: an illustrated guide” and “Neurology” (2007) (0)
Issue Information (2014) (0)
1999 ASCPT clinical pharmacology curriculum review course (1998) (0)
CLINICAL PHARMACOLOGY TO GUIDE THERAPEUTICS IN FRAIL OLDER MEN AND WOMEN (2017) (0)
Clinical Pharmacology Consultation from an Off‐Site Location Using Telemedicine: Report of a Pilot Study (1996) (0)
Contents Vol. 71, 1984 (1984) (0)
Pharmacologic properties of combination therapies (1996) (0)
Issue information (2015) (0)
Issue Information (2014) (0)
In vitro and in vivo evidence for inhibition of oct1 dna binding activity in cultured vascular smooth muscle cells (VSMCs) by nitric oxide (NO) (1996) (0)
Issue Information (2022) (0)
Improving Productivity in Pharmaceutical Research and Development : The Role of Clinical Pharmacology and Experimental Medicine (2015) (0)
Subject Index, Vol. 71, 1984 (1984) (0)
Oral Session I (OI) Drug Safety: From Genetics to Data Mining 12:45 pm – 1:45 pm (2013) (0)
Issue Information (2016) (0)
Chapter 26 – Drug Therapy in the Elderly (2012) (0)
Pharmacological properties of combination therapies for hypertension : Recent data on the safety and efficacy of newer therapies in the management of hypertension (1997) (0)
Dose-response characteristics of mibefradil, a selective T-type calcium channel blocker in the treatment of essential hypertension (1997) (0)
Discussion: recent data on the safety and efficacy of newer therapies in the management of hypertension. (1997) (0)
Reply (2001) (0)
Drug therapy. Current status of benzodiazepines. (1983) (0)
Development of Memory‐Enhancing Agents in the Treatment of Alzheimer's Disease (1987) (0)
Methodological Concerns for Clinical Trials in Geriatrics (1986) (0)
Evaluation of cholesterol synthesis in rats treated with drugs known to alter microsomal drug metabolizing enzyme activity (1974) (0)
with the highly significant reduction in clearance of the oxidized benzodiazepine diazepam. (1982) (0)
Desmethyldiazepam kinetics in obesity (1981) (0)
2017 Reviewer Acknowledgment (2018) (0)
HANDLS Co-Investigators (2004) (0)
Subject Index, Vol. 27 (Suppl 2), 1983 (1983) (0)
Acknowledgement to Referees (2013) (0)
Poster Walk IV (2015) (0)
Issue Information (2016) (0)
QTc prolongation and drugs [2] (multiple letters) (2001) (0)
Problem‐based teaching in clinical pharmacology: A training workshop (1993) (0)
Issue Information (2022) (0)
JPET #224766 1 Logic-based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells (2015) (0)
In Memoriam: David A. Flockhart, 1952–2015 (2016) (0)
1996 ASCPT clinical pharmacology curriculum review course (1995) (0)
Clinical judgment in geriatric hypertension. (1989) (0)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Interaction Between Nefazadone (NEF) and Terfenadine (TER) But Not NEF and Loratidine (LOR) (1999) (0)
Endothelin-1 (ET-1) induces prolonged AP-1 transcription factor DNA binding activity in vascular smooth muscle cells (VSMC) isolated from aged fischer 344 rats (1996) (0)
1994 ASCPT Workshop on Problem Based Teaching in Clinical Pharmacology—April 2, 1994 (1993) (0)
Genotyping for drug responsiveness: Learning from warfarin (2006) (0)
Herd 15 Program ADHIS (2015) (0)
Issue Information (2017) (0)
Aging: Its Influence on Drug Disposition and Effect (2000) (0)
A systems pharmacology approach to model tyrosine kinase inhibitor‐induced cardiotoxicity gene interaction networks (844.17) (2014) (0)
Contributors (2022) (0)
Paul Calabresi, 1930‐2003 (2004) (0)
SYNTH. VON 2,4-DIKETO-5-PHENYL-DELTA(5)-7-OXA-1,3-DIAZABICYCLO(4,4,0)DECAN UND 2,4-DIKETO-3-PHENYL-DELTA(5)-7-OXA-1,5-DIAZA-BICYCLO(4,4,0)DECAN (1973) (0)
Issue Information (2014) (0)
Benzodiazepines: A 1990 update. Roundtable discussion (1990) (0)
Wavelet-based analysis of FRET microscopy (2005) (0)
Impairment of antipyrine clearance with low-dose oral contraceptive steroid therapy (1980) (0)
Loratadine/nefazodone interaction [1] (multiple letters) (2002) (0)
Development of Drug Products for Older Adults (2019) (0)
USP metals testing (2008) (0)
Development of cardiomyopathy in response to chronic β‐adrenegric stimulation of transgenic mouse overexpressing the exon‐22 isoform of the human Cav1.2 channel α1C subunit as revealed by magnetic resonance imaging (2007) (0)
Acknowledgement to Referees (2014) (0)
Notes of the American Society for Clinical Pharmacology and Therapeutics (1991) (0)
Author response: Bidirectional interactions between indomethacin and the murine intestinal microbiota (2015) (0)
Oral Session II‐C (OII‐C) Having Your Drugs and Safety Too10:30 am – 11:45 am (2014) (0)
Halofantrine Safety, Tolerance and Metabolism Studies. (1997) (0)
Clinical Pharmacology in the USA: A Personal View of the Past, Present and Future (1995) (0)
Neural networks pattern recognition to predict abciximab pharmacodynamics using readily available patient characteristics (2003) (0)
Issue Information (2013) (0)
Cardiac drugs: adjusting their use in aging patients. (1987) (0)
Neural network model of orbofiban pharmacodynamics from sparse phase‐II data (2005) (0)
A Message from the President Come to Orlando, March 18–20, 1992 (1991) (0)
The concept of geriatric clinical pharmacology. Panel I: The ideal training program. (1987) (0)
Issue Information (2015) (0)
Workshop on drug utilization review. A practitioner's point of view. (1991) (0)
Predicting adverse cardiovascular events for tyrosine kinase inhibitors from molecular features (2016) (0)
International Union of Pharmacology Nomenclature and Pharmacological Reviews (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Darrell R. Abernethy?

Darrell R. Abernethy is affiliated with the following schools: